Last 12 months
Inside the activity.
0 purchase rows · 29 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 9 |
| Mar 2026 | 0 | 8 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2024 Filed Mar 1, 2024 21:55 UTC |
Plewman PatrickSVP for Diagnostic Services
|
Tax withholdingCommon Stock | 105 | $126.36 | $13,267.80 |
DisclosureSEC source: 0001022079-24-000085 · wk-form4_1709330104.xml · nonDerivative · entry 2 Plewman Patrick · CIK 0001497368 · SVP for Diagnostic Services 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,082 F1 · shares: Sale of common stock to satisfy tax obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:55 UTC |
Plewman PatrickSVP for Diagnostic Services
|
Tax withholdingCommon Stock | 228 | $126.36 | $28,810.08 |
DisclosureSEC source: 0001022079-24-000085 · wk-form4_1709330104.xml · nonDerivative · entry 1 Plewman Patrick · CIK 0001497368 · SVP for Diagnostic Services 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,187 F1 · shares: Sale of common stock to satisfy tax obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:51 UTC |
Doherty Catherine T.EVP, Regional Businesses
|
SaleCommon Stock | 5,557 | $126.57 | $703,349.49 |
DisclosureSEC source: 0001022079-24-000084 · wk-form4_1709329881.xml · nonDerivative · entry 3 Doherty Catherine T. · CIK 0001520897 · EVP, Regional Businesses 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,599 F2 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:51 UTC |
Doherty Catherine T.EVP, Regional Businesses
|
Tax withholdingCommon Stock | 557 | $126.36 | $70,382.52 |
DisclosureSEC source: 0001022079-24-000084 · wk-form4_1709329881.xml · nonDerivative · entry 2 Doherty Catherine T. · CIK 0001520897 · EVP, Regional Businesses 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,156 F1 · shares: Sale of common stock to satisfy tax obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:51 UTC |
Doherty Catherine T.EVP, Regional Businesses
|
Tax withholdingCommon Stock | 644 | $126.36 | $81,375.84 |
DisclosureSEC source: 0001022079-24-000084 · wk-form4_1709329881.xml · nonDerivative · entry 1 Doherty Catherine T. · CIK 0001520897 · EVP, Regional Businesses 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,713 F1 · shares: Sale of common stock to satisfy tax obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:50 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
Tax withholdingCommon Stock | 456 | $126.36 | $57,620.16 |
DisclosureSEC source: 0001022079-24-000083 · wk-form4_1709329804.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,089 F1 · shares: Sale of common stock to satisfy tax obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:50 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
Tax withholdingCommon Stock | 405 | $126.36 | $51,175.80 |
DisclosureSEC source: 0001022079-24-000083 · wk-form4_1709329804.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,545 F1 · shares: Sale of common stock to satisfy tax obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:49 UTC |
KUPPUSAMY KARTHIKSVP, Clinical Solutions
|
Tax withholdingCommon Stock | 68 | $126.36 | $8,592.48 |
DisclosureSEC source: 0001022079-24-000082 · wk-form4_1709329744.xml · nonDerivative · entry 2 KUPPUSAMY KARTHIK · CIK 0001955217 · SVP, Clinical Solutions 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,124 F1 · shares: Sale of common stock to satisfy tax obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:49 UTC |
KUPPUSAMY KARTHIKSVP, Clinical Solutions
|
Tax withholdingCommon Stock | 205 | $126.36 | $25,903.80 |
DisclosureSEC source: 0001022079-24-000082 · wk-form4_1709329744.xml · nonDerivative · entry 1 KUPPUSAMY KARTHIK · CIK 0001955217 · SVP, Clinical Solutions 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,192 F1 · shares: Sale of common stock to satisfy tax obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:46 UTC |
SAMAD SAMExecutive Vice President & CFO
|
Tax withholdingCommon Stock | 656 | $126.36 | $82,892.16 |
DisclosureSEC source: 0001022079-24-000081 · wk-form4_1709329574.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,332 F1 · shares: Sale of common stock to satisfy tax obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:44 UTC |
Davis J. E.Director · CEO and President
|
Tax withholdingCommon Stock | 1,804 | $126.36 | $227,953.44 |
DisclosureSEC source: 0001022079-24-000080 · wk-form4_1709329445.xml · nonDerivative · entry 2 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,968 F1 · shares: Sale of common stock to satisfy tax obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:44 UTC |
Davis J. E.Director · CEO and President
|
Tax withholdingCommon Stock | 3,216 | $126.36 | $406,373.76 |
DisclosureSEC source: 0001022079-24-000080 · wk-form4_1709329445.xml · nonDerivative · entry 1 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,772 F1 · shares: Sale of common stock to satisfy tax obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:43 UTC |
GARDNER MARK ASVP of Molecular Gen & Oncol
|
Tax withholdingCommon Stock | 262 | $126.36 | $33,106.32 |
DisclosureSEC source: 0001022079-24-000079 · wk-form4_1709329396.xml · nonDerivative · entry 1 GARDNER MARK A · CIK 0001955242 · SVP of Molecular Gen & Oncol 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,793 F1 · shares: Sale of common stock to satisfy tax obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:42 UTC |
Deppe Michael JSVP, Corp. Controller & CAO
|
Tax withholdingCommon Stock | 57 | $126.36 | $7,202.52 |
DisclosureSEC source: 0001022079-24-000078 · wk-form4_1709329341.xml · nonDerivative · entry 2 DEPPE MICHAEL J · CIK 0001771759 · SVP, Corp. Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,930 F1 · shares: Sale of common stock to satisfy tax obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:42 UTC |
Deppe Michael JSVP, Corp. Controller & CAO
|
Tax withholdingCommon Stock | 52 | $126.36 | $6,570.72 |
DisclosureSEC source: 0001022079-24-000078 · wk-form4_1709329341.xml · nonDerivative · entry 1 DEPPE MICHAEL J · CIK 0001771759 · SVP, Corp. Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,987 F1 · shares: Sale of common stock to satisfy tax obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 28, 2024 Filed Mar 1, 2024 21:41 UTC |
DELANEY MARK ESVP & Chief Commercial Officer
|
Tax withholdingCommon Stock | 225 | $126.36 | $28,431.00 |
DisclosureSEC source: 0001022079-24-000077 · wk-form4_1709329251.xml · nonDerivative · entry 1 DELANEY MARK E · CIK 0001955265 · SVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,603 F1 · shares: Sale of common stock to satisfy tax obligations arising from the vesting of a previous grant of restricted share units. Read SEC document |
| February 23, 2024 Filed Feb 23, 2024 21:34 UTC |
Gregg Vicky BDirector
|
SaleCommon Stock | 2,500 | $126.64 | $316,596.50 |
DisclosureSEC source: 0001022079-24-000052 · wk-form4_1708724051.xml · nonDerivative · entry 1 Gregg Vicky B · CIK 0001510304 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,329 Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:35 UTC |
Davis J. E.Director · CEO and President
|
Tax withholdingCommon Stock | 6,525 | $125.02 | $815,755.50 |
DisclosureSEC source: 0001022079-24-000067 · wk-form4_1709069732.xml · nonDerivative · entry 2 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,988 F2 · kind: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:35 UTC |
Davis J. E.Director · CEO and President
|
GrantCommon Stock | 13,390 | $125.02 | $1,674,017.80 |
DisclosureSEC source: 0001022079-24-000067 · wk-form4_1709069732.xml · nonDerivative · entry 1 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,513 F1 · kind: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2021, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:34 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
Tax withholdingCommon Stock | 2,825 | $125.02 | $353,181.50 |
DisclosureSEC source: 0001022079-24-000066 · wk-form4_1709069673.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,950 F2 · kind: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:34 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
GrantCommon Stock | 7,569 | $125.02 | $946,276.38 |
DisclosureSEC source: 0001022079-24-000066 · wk-form4_1709069673.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,775 F1 · kind: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2021, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:33 UTC |
Plewman PatrickSVP for Diagnostic Services
|
Tax withholdingCommon Stock | 869 | $125.02 | $108,642.38 |
DisclosureSEC source: 0001022079-24-000065 · wk-form4_1709069626.xml · nonDerivative · entry 2 Plewman Patrick · CIK 0001497368 · SVP for Diagnostic Services 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,415 F2 · kind: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:33 UTC |
Plewman PatrickSVP for Diagnostic Services
|
GrantCommon Stock | 2,388 | $125.02 | $298,547.76 |
DisclosureSEC source: 0001022079-24-000065 · wk-form4_1709069626.xml · nonDerivative · entry 1 Plewman Patrick · CIK 0001497368 · SVP for Diagnostic Services 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,284 F1 · kind: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2021, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:33 UTC |
Doherty Catherine T.EVP, Regional Businesses
|
Tax withholdingCommon Stock | 3,757 | $125.02 | $469,700.14 |
DisclosureSEC source: 0001022079-24-000064 · wk-form4_1709069583.xml · nonDerivative · entry 2 Doherty Catherine T. · CIK 0001520897 · EVP, Regional Businesses 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,357 F2 · kind: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:33 UTC |
Doherty Catherine T.EVP, Regional Businesses
|
GrantCommon Stock | 9,314 | $125.02 | $1,164,436.28 |
DisclosureSEC source: 0001022079-24-000064 · wk-form4_1709069583.xml · nonDerivative · entry 1 Doherty Catherine T. · CIK 0001520897 · EVP, Regional Businesses 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,114 F1 · kind: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2021, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:32 UTC |
KUPPUSAMY KARTHIKSVP, Clinical Solutions
|
Tax withholdingCommon Stock | 619 | $125.02 | $77,387.38 |
DisclosureSEC source: 0001022079-24-000063 · wk-form4_1709069533.xml · nonDerivative · entry 2 KUPPUSAMY KARTHIK · CIK 0001955217 · SVP, Clinical Solutions 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,397 F2 · kind: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:32 UTC |
KUPPUSAMY KARTHIKSVP, Clinical Solutions
|
GrantCommon Stock | 2,039 | $125.02 | $254,915.78 |
DisclosureSEC source: 0001022079-24-000063 · wk-form4_1709069533.xml · nonDerivative · entry 1 KUPPUSAMY KARTHIK · CIK 0001955217 · SVP, Clinical Solutions 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,016 F1 · kind: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2021, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:31 UTC |
Deppe Michael JSVP, Corp. Controller & CAO
|
Tax withholdingCommon Stock | 631 | $125.02 | $78,887.62 |
DisclosureSEC source: 0001022079-24-000062 · wk-form4_1709069467.xml · nonDerivative · entry 2 DEPPE MICHAEL J · CIK 0001771759 · SVP, Corp. Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,039 F2 · kind: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:31 UTC |
Deppe Michael JSVP, Corp. Controller & CAO
|
GrantCommon Stock | 1,689 | $125.02 | $211,158.78 |
DisclosureSEC source: 0001022079-24-000062 · wk-form4_1709069467.xml · nonDerivative · entry 1 DEPPE MICHAEL J · CIK 0001771759 · SVP, Corp. Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,670 F1 · kind: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2021, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 21:35 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
SaleCommon Stock | 661 | $126.14 | $83,378.54 |
DisclosureSEC source: 0001022079-24-000053 · wk-form4_1708724091.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,206 F2 · kind: This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 21:32 UTC |
Doherty Catherine T.EVP, Regional Businesses
|
SaleCommon Stock | 821 | $126.14 | $103,560.94 |
DisclosureSEC source: 0001022079-24-000050 · wk-form4_1708723905.xml · nonDerivative · entry 2 Doherty Catherine T. · CIK 0001520897 · EVP, Regional Businesses 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,800 F2 · kind: This sale reported wase effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 21:37 UTC |
Plewman PatrickSVP for Diagnostic Services
|
Tax withholdingCommon Stock | 139 | $125.02 | $17,377.78 |
DisclosureSEC source: 0001022079-24-000055 · wk-form4_1708724209.xml · nonDerivative · entry 1 Plewman Patrick · CIK 0001497368 · SVP for Diagnostic Services 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,896 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted share units. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 21:35 UTC |
Davis J. E.Director · CEO and President
|
Tax withholdingCommon Stock | 762 | $125.02 | $95,265.24 |
DisclosureSEC source: 0001022079-24-000054 · wk-form4_1708724127.xml · nonDerivative · entry 1 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,123 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted share units. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 21:35 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
Tax withholdingCommon Stock | 407 | $125.02 | $50,883.14 |
DisclosureSEC source: 0001022079-24-000053 · wk-form4_1708724091.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,867 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted share units. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 21:33 UTC |
KUPPUSAMY KARTHIKSVP, Clinical Solutions
|
Tax withholdingCommon Stock | 102 | $125.02 | $12,752.04 |
DisclosureSEC source: 0001022079-24-000051 · wk-form4_1708723984.xml · nonDerivative · entry 1 KUPPUSAMY KARTHIK · CIK 0001955217 · SVP, Clinical Solutions 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,977 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted share units. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 21:32 UTC |
Doherty Catherine T.EVP, Regional Businesses
|
Tax withholdingCommon Stock | 493 | $125.02 | $61,634.86 |
DisclosureSEC source: 0001022079-24-000050 · wk-form4_1708723905.xml · nonDerivative · entry 1 Doherty Catherine T. · CIK 0001520897 · EVP, Regional Businesses 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 71,621 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted share units. Read SEC document |
| February 21, 2024 Filed Feb 23, 2024 21:31 UTC |
Deppe Michael JSVP, Corp. Controller & CAO
|
Tax withholdingCommon Stock | 89 | $125.02 | $11,126.78 |
DisclosureSEC source: 0001022079-24-000049 · wk-form4_1708723821.xml · nonDerivative · entry 1 DEPPE MICHAEL J · CIK 0001771759 · SVP, Corp. Controller & CAO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,981 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted share units. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 01:06 UTC |
Davis J. E.Director · CEO and President
|
GrantNon-Qualifed Stock Option (right to buy) · Derivative | 92,779 | $0.00 Strike: $127.81 | $0.00 |
DisclosureSEC source: 0001022079-24-000036 · wk-form4_1708131954.xml · derivative · entry 2 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,779 Underlying: Common Stock · 92,779 shares Expires 2034-02-14 F2 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 01:06 UTC |
Davis J. E.Director · CEO and President
|
GrantCommon Stock | 22,251 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-24-000036 · wk-form4_1708131954.xml · nonDerivative · entry 1 Davis J. E. · CIK 0001599837 · Director · CEO and President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 124,885 F1 · security: Represents an award of restricted share units. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 01:05 UTC |
GARDNER MARK ASVP of Molecular Gen & Oncol
|
GrantNon-Qualifed Stock Option (right to buy) · Derivative | 9,376 | $0.00 Strike: $127.81 | $0.00 |
DisclosureSEC source: 0001022079-24-000035 · wk-form4_1708131917.xml · derivative · entry 2 GARDNER MARK A · CIK 0001955242 · SVP of Molecular Gen & Oncol 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,376 Underlying: Common Stock · 9,376 shares Expires 2034-02-14 F2 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 01:05 UTC |
GARDNER MARK ASVP of Molecular Gen & Oncol
|
GrantCommon Stock | 2,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-24-000035 · wk-form4_1708131917.xml · nonDerivative · entry 1 GARDNER MARK A · CIK 0001955242 · SVP of Molecular Gen & Oncol 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,055 F1 · security: Represents an award of restricted share units. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 01:04 UTC |
Plewman PatrickSVP for Diagnostic Services
|
GrantNon-Qualifed Stock Option (right to buy) · Derivative | 10,190 | $0.00 Strike: $127.81 | $0.00 |
DisclosureSEC source: 0001022079-24-000034 · wk-form4_1708131884.xml · derivative · entry 2 Plewman Patrick · CIK 0001497368 · SVP for Diagnostic Services 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,190 Underlying: Common Stock · 10,190 shares Expires 2034-02-14 F2 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 01:04 UTC |
Plewman PatrickSVP for Diagnostic Services
|
GrantCommon Stock | 2,446 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-24-000034 · wk-form4_1708131884.xml · nonDerivative · entry 1 Plewman Patrick · CIK 0001497368 · SVP for Diagnostic Services 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,035 F1 · security: Represents an award of restricted share units. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 01:04 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
GrantNon-Qualifed Stock Option (right to buy) · Derivative | 12,231 | $0.00 Strike: $127.81 | $0.00 |
DisclosureSEC source: 0001022079-24-000033 · wk-form4_1708131839.xml · derivative · entry 3 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,231 Underlying: Common Stock · 12,231 shares Expires 2034-02-14 F3 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 01:04 UTC |
PREVOZNIK MICHAEL ESVP & General Counsel
|
GrantCommon Stock | 2,935 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-24-000033 · wk-form4_1708131839.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,274 F1 · security: Represents an award of restricted share units. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 01:03 UTC |
SAMAD SAMExecutive Vice President & CFO
|
GrantNon-Qualifed Stock Option (right to buy) · Derivative | 22,835 | $0.00 Strike: $127.81 | $0.00 |
DisclosureSEC source: 0001022079-24-000032 · wk-form4_1708131808.xml · derivative · entry 2 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,835 Underlying: Common Stock · 22,835 shares Expires 2034-02-14 F2 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 01:03 UTC |
SAMAD SAMExecutive Vice President & CFO
|
GrantCommon Stock | 5,478 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-24-000032 · wk-form4_1708131808.xml · nonDerivative · entry 1 SAMAD SAM · CIK 0001694295 · Executive Vice President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,988 F1 · security: Represents an award of restricted share units. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 01:03 UTC |
KUPPUSAMY KARTHIKSVP, Clinical Solutions
|
GrantNon-Qualifed Stock Option (right to buy) · Derivative | 11,007 | $0.00 Strike: $127.81 | $0.00 |
DisclosureSEC source: 0001022079-24-000031 · wk-form4_1708131777.xml · derivative · entry 4 KUPPUSAMY KARTHIK · CIK 0001955217 · SVP, Clinical Solutions 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,007 Underlying: Common Stock · 11,007 shares Expires 2034-02-14 F3 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 01:03 UTC |
KUPPUSAMY KARTHIKSVP, Clinical Solutions
|
GrantCommon Stock | 2,641 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-24-000031 · wk-form4_1708131777.xml · nonDerivative · entry 1 KUPPUSAMY KARTHIK · CIK 0001955217 · SVP, Clinical Solutions 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,079 F1 · security: Represents an award of restricted share units. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 01:02 UTC |
DELANEY MARK ESVP & Chief Commercial Officer
|
GrantNon-Qualifed Stock Option (right to buy) · Derivative | 9,783 | $0.00 Strike: $127.81 | $0.00 |
DisclosureSEC source: 0001022079-24-000030 · wk-form4_1708131743.xml · derivative · entry 2 DELANEY MARK E · CIK 0001955265 · SVP & Chief Commercial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,783 Underlying: Common Stock · 9,783 shares Expires 2034-02-14 F2 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.